Skip to main content
Top
Published in: Trials 1/2012

Open Access 01-12-2012 | Research

Sponsors’ participation in conduct and reporting of industry trials: a descriptive study

Authors: Andreas Lundh, Lasse T Krogsbøll, Peter C Gøtzsche

Published in: Trials | Issue 1/2012

Login to get access

Abstract

Background

Bias in industry-sponsored trials is common and the interpretation of the results can be particularly distorted in favour of the sponsor’s product. We investigated sponsors’ involvement in the conduct and reporting of industry-sponsored trials.

Methods

We included all industry-sponsored trials published in The Lancet in 2008 and 2009 and corresponding trial protocols provided by The Lancet. For each protocol and publication, we extracted information on trial conduct and reporting.

Results

We identified 169 publications of randomised trials and included 69 (41%) that were industry-sponsored, and 12 (7%) industry-funded but seemingly independently conducted as a subsample. Entry of data into the study database was done independently by academic authors without the involvement of the sponsor or a contract research organisation in one of the 69 trials. Two trials had independent data analysis and one independent reporting of results. In 11 of the trials, there was a discrepancy between the information in the protocols and papers concerning who analysed the data. In four of the 12 seemingly independent trials, the protocol described sponsors’ involvement in writing the report while the published paper explicitly stated that the sponsor was not involved.

Conclusions

The sponsors are usually involved in the analysis and reporting of results in industry-sponsored trials, but their exact role is not always clear from the published papers. Journals should require more transparent reporting of the sponsors’ role in crucial elements such as data processing, statistical analysis and writing of the manuscript and should consider requiring access to trial protocols, independent data analysis and submission of the raw data.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dorsey ER, de Roulet J, Thompson JP, Reminick JI, Thai A, White-Stellato Z, Beck CA, George BP, Moses H: Funding of US biomedical research, 2003–2008. JAMA. 2010, 303: 137-143. 10.1001/jama.2009.1987.CrossRefPubMedPubMedCentral Dorsey ER, de Roulet J, Thompson JP, Reminick JI, Thai A, White-Stellato Z, Beck CA, George BP, Moses H: Funding of US biomedical research, 2003–2008. JAMA. 2010, 303: 137-143. 10.1001/jama.2009.1987.CrossRefPubMedPubMedCentral
2.
go back to reference Lundh A, Barbateskovic M, Hróbjartsson A, Gøtzsche PC: Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. PLoS Med. 2010, 7: e1000354-10.1371/journal.pmed.1000354.CrossRefPubMedPubMedCentral Lundh A, Barbateskovic M, Hróbjartsson A, Gøtzsche PC: Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. PLoS Med. 2010, 7: e1000354-10.1371/journal.pmed.1000354.CrossRefPubMedPubMedCentral
3.
go back to reference Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003, 326: 1167-1170. 10.1136/bmj.326.7400.1167.CrossRefPubMedPubMedCentral Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003, 326: 1167-1170. 10.1136/bmj.326.7400.1167.CrossRefPubMedPubMedCentral
4.
go back to reference Sismondo S: Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008, 29: 109-113. 10.1016/j.cct.2007.08.001.CrossRefPubMed Sismondo S: Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008, 29: 109-113. 10.1016/j.cct.2007.08.001.CrossRefPubMed
5.
go back to reference Bero LA, Rennie D: Influences on the quality of published drug studies. Int J Technol Assess Health Care. 1996, 12: 209-237. 10.1017/S0266462300009582.CrossRefPubMed Bero LA, Rennie D: Influences on the quality of published drug studies. Int J Technol Assess Health Care. 1996, 12: 209-237. 10.1017/S0266462300009582.CrossRefPubMed
6.
go back to reference Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan A-W, Cronin E, Decullier E, Easterbrook PJ, Von Elm E, Gamble C, Ghersi D, Ioannidis JP, Simes J, Williamson PR: Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One. 2008, 3: e3081-10.1371/journal.pone.0003081.CrossRefPubMedPubMedCentral Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan A-W, Cronin E, Decullier E, Easterbrook PJ, Von Elm E, Gamble C, Ghersi D, Ioannidis JP, Simes J, Williamson PR: Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One. 2008, 3: e3081-10.1371/journal.pone.0003081.CrossRefPubMedPubMedCentral
7.
go back to reference DeAngelis CD, Fontanarosa PB: The importance of independent academic statistical analysis. Biostatistics. 2010, 11: 383-384. 10.1093/biostatistics/kxq027.CrossRefPubMed DeAngelis CD, Fontanarosa PB: The importance of independent academic statistical analysis. Biostatistics. 2010, 11: 383-384. 10.1093/biostatistics/kxq027.CrossRefPubMed
8.
go back to reference Schulman KA, Seils DM, Timbie JW, Sugarman J, Dame LA, Weinfurt KP, Mark DB, Califf RM: A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med. 2002, 347: 1335-1341. 10.1056/NEJMsa020349.CrossRefPubMed Schulman KA, Seils DM, Timbie JW, Sugarman J, Dame LA, Weinfurt KP, Mark DB, Califf RM: A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med. 2002, 347: 1335-1341. 10.1056/NEJMsa020349.CrossRefPubMed
9.
go back to reference Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW: Constraints on publication rights in industry-initiated clinical trials. JAMA. 2006, 295: 1645-1646. 10.1001/jama.295.14.1645.PubMed Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW: Constraints on publication rights in industry-initiated clinical trials. JAMA. 2006, 295: 1645-1646. 10.1001/jama.295.14.1645.PubMed
10.
go back to reference Lundh A, Krogsbøll LT, Gøtzsche PC: Access to data in industry-sponsored trials. Lancet. 2011, 378: 1995-1996.CrossRefPubMed Lundh A, Krogsbøll LT, Gøtzsche PC: Access to data in industry-sponsored trials. Lancet. 2011, 378: 1995-1996.CrossRefPubMed
11.
go back to reference Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW: Ghost authorship in industry-initiated randomised trials. PLoS Med. 2007, 4: e19-10.1371/journal.pmed.0040019.CrossRefPubMedPubMedCentral Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW: Ghost authorship in industry-initiated randomised trials. PLoS Med. 2007, 4: e19-10.1371/journal.pmed.0040019.CrossRefPubMedPubMedCentral
12.
go back to reference Rose SL, Krzyzanowska MK, Joffe S: Relationships between authorship contributions and authors’ industry financial ties among oncology clinical trials. J Clin Oncol. 2010, 28: 1316-1321. 10.1200/JCO.2008.21.6606.CrossRefPubMedPubMedCentral Rose SL, Krzyzanowska MK, Joffe S: Relationships between authorship contributions and authors’ industry financial ties among oncology clinical trials. J Clin Oncol. 2010, 28: 1316-1321. 10.1200/JCO.2008.21.6606.CrossRefPubMedPubMedCentral
13.
go back to reference Tuech JJ, Moutel G, Pessaux P, Thoma V, Schraub S, Herve C: Disclosure of competing financial interests and role of sponsors in phase III cancer trials. Eur J Cancer. 2005, 41: 2237-2240. 10.1016/j.ejca.2004.12.036.CrossRefPubMed Tuech JJ, Moutel G, Pessaux P, Thoma V, Schraub S, Herve C: Disclosure of competing financial interests and role of sponsors in phase III cancer trials. Eur J Cancer. 2005, 41: 2237-2240. 10.1016/j.ejca.2004.12.036.CrossRefPubMed
14.
go back to reference Healy D: Let them eat Prozac. 2004, New York: New York University Press Healy D: Let them eat Prozac. 2004, New York: New York University Press
16.
go back to reference Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000, 343: 1520-1528. 10.1056/NEJM200011233432103. 2 p following 1528CrossRefPubMed Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000, 343: 1520-1528. 10.1056/NEJM200011233432103. 2 p following 1528CrossRefPubMed
17.
go back to reference Curfman GD, Morrissey S, Drazen JM: Expression of concern: Bombardier et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,” N Engl J Med 2000; 343: 1520–8. N Engl J Med. 2005, 353: 2813-2814. 10.1056/NEJMe058314.CrossRefPubMed Curfman GD, Morrissey S, Drazen JM: Expression of concern: Bombardier et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,” N Engl J Med 2000; 343: 1520–8. N Engl J Med. 2005, 353: 2813-2814. 10.1056/NEJMe058314.CrossRefPubMed
18.
go back to reference Psaty BM, Prentice RL: Minimizing bias in randomized trials: the importance of blinding. JAMA. 2010, 304: 793-794. 10.1001/jama.2010.1161.CrossRefPubMed Psaty BM, Prentice RL: Minimizing bias in randomized trials: the importance of blinding. JAMA. 2010, 304: 793-794. 10.1001/jama.2010.1161.CrossRefPubMed
20.
go back to reference Psaty BM, Kronmal RA: Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA. 2008, 299: 1813-1817. 10.1001/jama.299.15.1813.CrossRefPubMed Psaty BM, Kronmal RA: Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA. 2008, 299: 1813-1817. 10.1001/jama.299.15.1813.CrossRefPubMed
22.
go back to reference Sismondo S: How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med. 2008, 66: 1909-1914. 10.1016/j.socscimed.2008.01.010.CrossRefPubMed Sismondo S: How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med. 2008, 66: 1909-1914. 10.1016/j.socscimed.2008.01.010.CrossRefPubMed
23.
24.
go back to reference McGauran N, Wieseler B, Kreis J, Schüler Y-B, Kölsch H, Kaiser T: Reporting bias in medical research - a narrative review. Trials. 2010, 11: 37-10.1186/1745-6215-11-37.CrossRefPubMedPubMedCentral McGauran N, Wieseler B, Kreis J, Schüler Y-B, Kölsch H, Kaiser T: Reporting bias in medical research - a narrative review. Trials. 2010, 11: 37-10.1186/1745-6215-11-37.CrossRefPubMedPubMedCentral
25.
go back to reference Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schünemann H, Cook DJ, Lutz K, Ribic CM, Vale N, STOPIT-2 Study Group: Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010, 303: 1180-1187. 10.1001/jama.2010.310.CrossRefPubMed Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schünemann H, Cook DJ, Lutz K, Ribic CM, Vale N, STOPIT-2 Study Group: Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010, 303: 1180-1187. 10.1001/jama.2010.310.CrossRefPubMed
26.
go back to reference Trotta F, Apolone G, Garattini S, Tafuri G: Stopping a trial early in oncology: for patients or for industry?. Ann Oncol. 2008, 19: 1347-1353. 10.1093/annonc/mdn042.CrossRefPubMed Trotta F, Apolone G, Garattini S, Tafuri G: Stopping a trial early in oncology: for patients or for industry?. Ann Oncol. 2008, 19: 1347-1353. 10.1093/annonc/mdn042.CrossRefPubMed
27.
go back to reference Wager E, Mhaskar R, Warburton S, Djulbegovic B: JAMA published fewer industry-funded studies after introducing a requirement for independent statistical analysis. PLoS One. 2010, 5: e13591-10.1371/journal.pone.0013591.CrossRefPubMedPubMedCentral Wager E, Mhaskar R, Warburton S, Djulbegovic B: JAMA published fewer industry-funded studies after introducing a requirement for independent statistical analysis. PLoS One. 2010, 5: e13591-10.1371/journal.pone.0013591.CrossRefPubMedPubMedCentral
28.
go back to reference Strengthening the credibility of clinical research. Lancet. 2010, 375: 1225-10.1016/S0140-6736(10)60523-5. Strengthening the credibility of clinical research. Lancet. 2010, 375: 1225-10.1016/S0140-6736(10)60523-5.
Metadata
Title
Sponsors’ participation in conduct and reporting of industry trials: a descriptive study
Authors
Andreas Lundh
Lasse T Krogsbøll
Peter C Gøtzsche
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Trials / Issue 1/2012
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-13-146

Other articles of this Issue 1/2012

Trials 1/2012 Go to the issue